Obviousness

To analyze the obviousness of US Patent 12576084 under 35 U.S.C. § 103, we consider what a person having ordinary skill in the art (POSA) would have known or been motivated to do before the patent's priority date of April 27, 2018. Since no external prior art documents are provided beyond the priority date and general keywords, this analysis will rely on the information presented within the patent itself regarding the state of the art at the time of the invention.

The independent claims of US12576084 are:

• Claim 1: A method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF1) antagonist or a pharmaceutically acceptable salt thereof.
• Claim 7: A method of treating or preventing TART or OART, comprising administering to a subject in need thereof a compound of structural Formula (I) or a pharmaceutically acceptable salt thereof, with specified definitions for R1, R2, R3, R4, Ra, and Rb groups.
• Claim 24: A method of treating or preventing TART or OART, comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I) (as defined in Claim 7) and a pharmaceutically acceptable excipient.

Hypothetical Prior Art Based on Patent Disclosures (Pre-April 27, 2018)

For the purpose of this obviousness analysis, we assume the following knowledge was available to a POSA prior to the priority date, based on the background and summary sections of US12576084:

Prior Art Reference A (Pathophysiology of TART/OART): It was known that Testicular Adrenal Rest Tumors (TART) and Ovarian Adrenal Rest Tumors (OART) are ACTH-responsive lesions. Their growth and hyperplasia are stimulated by high levels of adrenocorticotropic hormone (ACTH). The patent explicitly states: "Testicular adrenal rest tumors (TART) and ovarian adrenal rest tumors (OART) are ACTH-responsive lesions of the testes and ovaries derived from adrenal tissue interchelated within these organs during embryogenesis. In response to high ACTH, hyperplasia of this tissue occurs, resulting in single or multiple lesions that may cause pain and infertility."

Prior Art Reference B (CRF1 Antagonists and CAH): It was known that Congenital Adrenal Hyperplasia (CAH) is a serious genetic disorder characterized by the overproduction of ACTH. CRF1 antagonists were known to reduce excess ACTH levels and were being investigated or proposed as a therapy to improve clinical and biochemical sequelae of CAH. The patent states: "Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a serious genetic disorder characterized by impaired adrenal synthesis of cortisol and consequent overproduction of adrenocorticotropic hormone (ACTH)... Compound 1 may be a potent, selective, nonsteroidal, oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist that reduces excess ACTH, 17OHP, and A4 to improve clinical and biochemical sequelae of CAH." This also implies that "Compound 1" (a specific compound falling under Formula (I)) was a known CRF1 antagonist with activity in reducing ACTH for CAH.

Prior Art Reference C (Existing Treatment Challenges): There was an acknowledged need for non-steroidal, non-surgical solutions to control, shrink, or reduce TART. The patent notes: "Currently, there are no non-steroidal, non-surgical solutions to control, shrink, or reduce TART."

Motivation to Combine Prior Art References

A person having ordinary skill in the art (POSA) in the field of endocrinology or urology/gynecology would have been motivated to combine the teachings of Prior Art References A, B, and C as follows:

1. Understanding the Underlying Mechanism (Prior Art A): The POSA would recognize that TART/OART are directly linked to elevated ACTH levels. This understanding would naturally lead to considering therapeutic strategies aimed at reducing ACTH.
2. Known Solution for ACTH Reduction (Prior Art B): The POSA would be aware that CRF1 antagonists are a class of compounds capable of reducing ACTH levels. Furthermore, the explicit mention of "Compound 1" and its role in improving CAH by reducing ACTH would highlight the utility of such compounds for conditions characterized by ACTH overproduction.
3. Addressing an Unmet Need (Prior Art C): Given the limitations of existing treatments for TART (surgical or steroid-based), a strong motivation would exist to explore novel, less invasive, and potentially more targeted therapeutic approaches. Targeting the root cause of ACTH-driven tumor growth with a CRF1 antagonist would be a logical scientific step.
4. Clinical Link Between CAH and TART/OART: The patent itself identifies TART/OART as a "complication of congenital adrenal hyperplasia (CAH)". This direct link would provide a particularly strong motivation for a POSA to consider applying a treatment effective for the primary condition (CAH via CRF1 antagonism) to its known complications (TART/OART), especially since both are characterized by ACTH responsiveness.

Obviousness of the Claims

Based on this combination of prior art and motivation:

• Claim 1 (General CRF1 Antagonist): Administering a CRF1 antagonist to treat ACTH-responsive TART/OART would be obvious. A POSA, knowing that TART/OART are stimulated by ACTH (Prior Art A) and that CRF1 antagonists reduce ACTH (Prior Art B), would foresee that reducing ACTH with a CRF1 antagonist could control or shrink these tumors. The lack of effective non-surgical/non-steroidal options (Prior Art C) would further compel a POSA to explore this logical therapeutic approach.
• Claims 7 and 24 (Specific Formula (I) Compounds/Compositions): If the general concept of using CRF1 antagonists for TART/OART is obvious, then the use of specific, known CRF1 antagonists, such as those described by Formula (I) or the exemplified "Compound 1," would also be obvious for this purpose. The patent explicitly states that Compound 1 reduces ACTH and improves CAH symptoms. Given the connection between CAH and TART/OART, and the known ACTH-responsive nature of the tumors, using a known CRF1 antagonist (like Compound 1) to treat them would be a straightforward application of existing knowledge. The inclusion of "pharmaceutically acceptable salt thereof" and "pharmaceutically acceptable excipient" reflects routine pharmaceutical formulation practices and does not confer non-obviousness to the method claims.

Therefore, the claims of US Patent 12576084 appear obvious under 35 U.S.C. § 103, as a POSA would have been motivated to combine the known ACTH-responsiveness of TART/OART with the known ACTH-reducing capabilities of CRF1 antagonists, particularly in the context of CAH, to address an unmet medical need.